Expertise in
20
conditions

Dr. Anthony S. Stein

Oncology
Anthony S. Stein, M.D.
1500 Duarte Rd, 
Duarte, CA 
Expertise in
20
conditions
Anthony S. Stein, M.D.
1500 Duarte Rd, 
Duarte, CA 

Overview

Anthony Stein is an Oncologist practicing medicine in Duarte, California.

Dr. Stein is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Leukemia, Bone Marrow Aspiration, and Colonoscopy.

He is actively involved in clinical research, co-authoring 204 peer reviewed articles and participating in 10 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Anthony S. Stein, M.D.
1500 Duarte Rd, Duarte, CA 91010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase II Study of Total Marrow and Lymphoid Irradiation (TMLI) Given in Combination With Cyclophosphamide and Etoposide as Conditioning for Allogeneic (HSCT) in Patients With High-Risk Acute Lymphocytic or Myelogenous Leukemia
Phase II Study of Total Marrow and Lymphoid Irradiation (TMLI) Given in Combination With Cyclophosphamide and Etoposide as Conditioning for Allogeneic (HSCT) in Patients With High-Risk Acute Lymphocytic or Myelogenous Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Drug, Procedure, Radiation
Study Drugs: Etoposide, Cyclophosphamide
Study Phase: Phase 2
Pilot Study of Total Marrow/Lymphoid Irradiation (TMLI) Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplant (HCT) Followed by Post Transplant Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis for Acute Myelogenous Leukemia in Complete Remission
Pilot Study of Total Marrow/Lymphoid Irradiation (TMLI) Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplant (HCT) Followed by Post Transplant Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis for Acute Myelogenous Leukemia in Complete Remission
Enrollment Status: Suspended
Publish Date: February 17, 2026
Intervention Type: Other, Drug, Procedure, Biological, Radiation
Study Drugs: Cyclophosphamide, Filgrastim, Tacrolimus
Study Phase: Phase 1
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR
A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR
Enrollment Status: Terminated
Publish Date: October 17, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Tagraxofusp in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Tagraxofusp in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Enrollment Status: Completed
Publish Date: August 01, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Phase 1/2 Study of PD-616 and Low-dose Cytarabine in Patients With Untreated or Relapsed/Refractory Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
An Open-Label, Phase 1/2 Study of PD-616 and Low-dose Cytarabine in Patients With Untreated or Relapsed/Refractory Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Enrollment Status: Terminated
Publish Date: July 24, 2018
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: May 09, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

204 Total Publications

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.
Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.
Journal: The New England journal of medicine
Published: September 02, 2026
Similar Doctors
Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required

City Of Hope - Duarte Main Campus

1500 E Duarte Rd, 
Duarte, CA 
 (0.1 miles away)
626-256-4673
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alex Herrera is an Oncologist practicing medicine in Duarte, CA. He has been practicing medicine for over 17 years. Dr. Herrera is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Colonoscopy. Dr. Herrera is board certified in American Board Of Internal Medicine, Hematology and American Board Of Internal Medicine, Oncology.

Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required

City Of Hope Comprehensive Cancer Center-Duarte

1500 Duarte Rd, 
Duarte, CA 
 (0.1 miles away)
888-304-3959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sumanta Pal is an Oncologist practicing medicine in Duarte, California. Dr. Pal is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Bladder Cancer, Nephrectomy, and Lymphadenectomy.

Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required

City Of Hope Comprehensive Cancer Center-Duarte

1500 Duarte Rd, 
Duarte, CA 
 (0.1 miles away)
626-275-8064
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hope Rugo is an Oncologist practicing medicine in Duarte, California. Dr. Rugo is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Bone Marrow Aspiration, and Vertebroplasty.

Frequently Asked Questions about Dr. Anthony S. Stein

How do I make an appointment with Dr. Anthony S. Stein?

You can book an appointment with Dr. Anthony S. Stein by calling their office at 800-826-4673. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Anthony S. Stein a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Anthony S. Stein is classified as an Elite expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Anthony S. Stein specialize in?

While Dr. Anthony S. Stein is a Oncology, they have specific expertise in Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), and Leukemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Anthony S. Stein participate in research or clinical trials?

Yes. Dr. Anthony S. Stein has published 204 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Anthony S. Stein's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Anthony S. Stein accept my insurance?

Dr. Anthony S. Stein accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 800-826-4673 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stein's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile